LNAI Stock Soars Pre-Market After Immune Cell Therapy Gains Licensee Interest

• The company has now proposed an early-stage clinical trial to evaluate the cell therapy.
• Lunai is also advancing additional studies and expanding the clinical reach of its DCCT platform through collaborations with investigators in non-small cell lung cancer and prostate cancer.
• The company is also preparing for formal licensing negotiations and pursuing activities ahead of the commencement of human clinical trials in early 2026.

Shares of Lunai Bioworks (LNAI) jumped 26% in the pre-market session on Tuesday after the company announced that it has secured its first letter of intent (LOI) to license its next-generation immune cell therapy.

"We are seeing accelerating validation from both researchers and industry partners," said CEO David Weinstein. He added that the early licensing activity reflects growing confidence in the platform's potential to unlock scalable treatments.

Data For Cell Therapy

The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.

The company has now proposed an early-stage clinical trial to evaluate the cell therapy, manufactured from healthy donor cells and stored ready-to-use, across several high-risk tumors, including pancreatic cancer, which has a poor survival rate.

Plans Ahead

Lunai is also advancing additional studies and expanding the clinical reach of its DCCT platform through collaborations with investigators in non-small cell lung cancer and prostate cancer.

Additionally, it is preparing for formal licensing negotiations and pursuing activities ahead of the commencement of human clinical trials in early 2026.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around LNAI jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.

LNAI stock is down by 85% this year and by about 75% over the past 12 months. 

Also See: Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study

For updates and corrections, email newsroom[at]stocktwits[dot]com

Share

·

Add us on